<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240615062136N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-10-18</date_registration>
      <primary_sponsor>Oroumia University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the Effect of Genicular Artery Embolization for the Treatment of Knee Osteoarthritis Pain</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the Effect of Genicular Artery Embolization for the Treatment of Knee Pain Secondary to Osteoarthritis in patients refferd to Urmia Imam Khomeini Hospital</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-09-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>23</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/78238</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.</study_design>
      <phase>3</phase>
      <hc_freetext>Osteoarthritis of Knee.</hc_freetext>
      <i_freetext>Intervention group: Patients who undergo embolization of the genicular artery of one knee. Both knees of each patient are examined, and the knees are randomly assigned to either intervention or control (23 intervention knees and 23 control knees). A 2.8-F microcatheter is selectively used to target the genicular arteries in the knee area with the most severe pain. Digital subtraction angiography (DSA) is performed at a low frame rate (1-2 frames per second) and continues until "tumor blush" is observed in delayed images. Embolization is then performed using 150-250 micron embolic particles. The embolization technique involves mixing the particles in a solution with 10 ml of contrast medium. After mixing the liquid to create a homogeneous solution, 2 ml is injected. The injection is performed with repeated digital subtraction angiography until tumor blush is no longer observed in delayed images. This process is repeated for each genicular artery feeding the knee area with the most severe pain. A repeat angiography via the femoral artery is performed to eliminate any untreated branches. All individuals receive an antibiotic dose before the procedure and for 5 days afterward. Pain medication is prescribed for the post-embolization period (up to 1 week after the procedure) in all groups. Patients are discharged 6 hours after the procedure. An initial follow-up phone call is made the day after the procedure to assess acute events. Subsequent follow-ups are conducted one month after the procedure. All post-operative data is collected and recorded by study staff..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Dependent on the approval of the hospital's ethics committee</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Parisa Noorabadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Khomeini Hospital, Ershad St., Modarres Blvd.</address>
        <city>Urmia</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5715789397</zip>
        <telephone>+98 44 3345 7286</telephone>
        <email>noorabadi.par@umsu.ac.ir</email>
        <affiliation>Oroumia University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Parisa Noorabadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Khomeini Hospital, Ershad St., Modarres Blvd.</address>
        <city>Urmia</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5715789397</zip>
        <telephone>+98 44 3345 7286</telephone>
        <email>noorabadi.par@umsu.ac.ir</email>
        <affiliation>Oroumia University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age between 45 and 75 years with symptoms of knee pain in both knees
Radiographic findings in both knees with a grade of 2 to 4 based on the Kellgren-Lawrence classification
VAS score above 50/100 for both knees
Pain resistant to medical and supportive treatments for a duration of 3 months
All patients must agree not to use any oral or injectable painkillers and supplements during the study period and, if necessary, take medications according to the study protocol</inclusion_criteria>
      <agemin>45 years</agemin>
      <agemax>75 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnancy
GFR &lt; 60 ml/min/1.73m²
Sensitivity to contrast agents
BMI &gt; 40 kg/m²
History of joint injection in the last 3 months
Joint infection or inflammatory joint disease
Life expectancy of less than 2.5 years
Platelet count less than 30,000 per microliter
Allergy to iodinated contrast agents
Presence of joint prosthesis or history of joint surgery
Absence of palpable pulse</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M17</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Osteoarthritis of knee</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients who undergo embolization of the genicular artery of one knee. Both knees of each patient are examined, and the knees are randomly assigned to either intervention or control (23 intervention knees and 23 control knees). A 2.8-F microcatheter is selectively used to target the genicular arteries in the knee area with the most severe pain. Digital subtraction angiography (DSA) is performed at a low frame rate (1-2 frames per second) and continues until "tumor blush" is observed in delayed images. Embolization is then performed using 150-250 micron embolic particles. The embolization technique involves mixing the particles in a solution with 10 ml of contrast medium. After mixing the liquid to create a homogeneous solution, 2 ml is injected. The injection is performed with repeated digital subtraction angiography until tumor blush is no longer observed in delayed images. This process is repeated for each genicular artery feeding the knee area with the most severe pain. A repeat angiography via the femoral artery is performed to eliminate any untreated branches. All individuals receive an antibiotic dose before the procedure and for 5 days afterward. Pain medication is prescribed for the post-embolization period (up to 1 week after the procedure) in all groups. Patients are discharged 6 hours after the procedure. An initial follow-up phone call is made the day after the procedure to assess acute events. Subsequent follow-ups are conducted one month after the procedure. All post-operative data is collected and recorded by study staff.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain Score. Timepoint: Before, after one month and three months of the intervention. Method of measurement: Visual Analogue Scale.</prim_outcome>
      <prim_outcome>Functional Performance. Timepoint: Before, after one month and three months of the intervention. Method of measurement: The Western Ontario and McMaster Universities Osteoarthritis Index.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Oroumia University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-07-10</approval_date>
        <contact_name>Ethics Committee of Imam Khomeini Hospital, Urmia University of Medical Sciences</contact_name>
        <contact_address>Imam Khomeini Hospital, Ershad St., Modarres Blvd. Urmia West Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
